SCHEMBL5840804

SCHEMBL5840804

Cc1cc(NCCN2CCOCC2)ccc1Br

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.55
HBB P68871 1/20 0.55
CYP3A4 P08684 4/20 0.52
NPC1 O15118 1/20 0.52
CYP2C19 P33261 1/20 0.52
HSP90AA1 P07900 1/20 0.52
THRB P10828 1/20 0.51
CHRM1 P11229 2/20 0.47
LMNA P02545 2/20 0.47
CYP1A2 P05177 2/20 0.47
ACHE P22303 2/20 0.47
POLB P06746 1/20 0.47
ATM Q13315 1/20 0.47
CYP2D6 P10635 1/20 0.47
CNR1 P21554 1/20 0.47
HTR2B P41595 1/20 0.47
KCNH2 Q12809 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
ABL1 P00519 1/20 0.46
BCR P11274 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21247508 0.86 CYP3A4 (0.52) MAPK1CYP3A4NPC1CYP2C19HSP90AA1
SCHEMBL30764865 0.86 CYP3A4 (0.52) MAPK1CYP3A4NPC1CYP2C19HSP90AA1
SCHEMBL13841388 0.79 TSHR (0.60) CYP3A4NPC1CYP2C19LMNACYP1A2
SCHEMBL14419464 0.78 POLB (0.54) MAPK1CYP3A4NPC1CYP2C19LMNA
SCHEMBL1911909 0.78 LMNA (0.57) MAPK1CYP3A4NPC1CYP2C19LMNA
SCHEMBL22995880 0.78 ALDH1A1 (0.55) CYP3A4NPC1CYP2C19LMNAPOLB
SCHEMBL13164567 0.77 RECQL (0.67) CYP3A4CYP2C19CHRM1LMNACYP1A2
SCHEMBL4855643 0.76 RAB9A (0.58) CYP3A4NPC1CHRM1LMNACYP1A2
SCHEMBL4168121 0.76 POLB (0.80) MAPK1HBBCYP3A4CYP2C19CYP1A2
SCHEMBL13065567 0.76 ALDH1A1 (0.80) MAPK1CYP3A4CYP2C19POLBCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7138530-B2 Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2006-11-21 US disclosed
US-7109354-B2 Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2006-09-19 US disclosed
EP-1549632-A4 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS DIMENSIONAL PHARM INC (US) 2005-11-09 EP disclosed
US-20050234081-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions SUBASINGHE NALIN 2005-10-20 US disclosed
EP-1549632-A1 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2005-07-06 EP disclosed
US-20040009995-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. 2004-01-15 US disclosed
WO-2003099805-A1 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234081-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions C5, C9, C1R MAPK1 1502/4885HBB 1763/4885CYP3A4 1530/4885
US-20040009995-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions C5, C9, C1R MAPK1 1012/4885HBB 2329/4885CYP3A4 1112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.